Physician profile
James B Fleming
NPI 1841525631
$2,501.80
in general payments reported to CMS, 2019-2025
26 companies · $683 in 2025
The $683 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $71.64 · 2021: $256 · 2022: $355 · 2023: $484 · 2024: $455 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,621.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $655.87 | 2022-2025 | |
| Glaxosmithkline, LLC. | $333.71 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $249.05 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $244.02 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Vanda Pharmaceuticals INC. | $225.68 | 2021-2023 | Hetlioz |
| Alkermes, INC. | $134.64 | 2019-2025 | Vivitrol, Vivitrol |
| Bayer Healthcare Pharmaceuticals INC. | $115.57 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $87.20 | 2021-2025 | |
| Corcept Therapeutics | $69.62 | 2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $67.90 | 2022-2025 | Airsupra, Farxiga |
| Xeris Pharmaceuticals, INC. | $46.53 | 2023-2024 | Gvoke Hypopen |
| Exact Sciences Corporation | $36.65 | 2024-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.37 | 2025 | Caplyta |
| Astellas Pharma US INC | $21.31 | 2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.12 | 2024 | Jardiance, Synjardy, Tradjenta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $18.25 | 2021 | |
| Insulet Corporation | $17.98 | 2025 | Omnipod |
| Merck Sharp & Dohme LLC | $16.74 | 2025 | Verquvo |
| Dexcom, INC. | $16.42 | 2025 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $16.37 | 2019 | |
| Braeburn INC. | $15.21 | 2024 | Brixadi |
| Currax Pharmaceuticals LLC | $14.30 | 2021 | |
| Pfizer INC. | $13.55 | 2025 | |
| Amgen INC. | $13.27 | 2024 | Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $12.38 | 2022 | |
| Phathom Pharmaceuticals, INC. | $3.09 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Fleming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.